News

CanPharma News Feed

No more posts
cbdinol-bodegon-1200x968.jpg
19/Feb/2020

CanPharma extends its high-quality product range with the certified full spectrum extract, CBDinol. CBDinol with a CBD concentration of 6% (PZN 16353901) or 15% (PZN 16353870) is now exclusively available for pharmacies from CanPharma.

CBDinol is made from EU certified hemp and has no psychoactive effect due to its THC content of less than 0.2%. It is well tolerated and easy to use. CBDinol consists of extracted hemp seed oil and contains the entire spectrum of cannabinoids, terpenes and nutrients. This is guaranteed by a gentle manufacturing process and responsible cultivation of the hemp plants.

CBDinol is obtained from a special extraction process using ethanol, with no addition of any additives. All product batches are laboratory tested to ensure the highest possible quality and stability of the product. The hemp plants are free from GMOs and chemical fertilisers, and are also free from gluten, preservatives and dyes. The production runs accordingly to strict European standards.

www.cbdinol.com


CBD_psoriasis-1200x800.jpg
12/Feb/2020

Hope for lower cost medicines for psoriasis by using CBD

Psoriasis is often triggered by stress which can lead to anxiety and depression due to fear of being ridiculed by the symptoms such as scaling of the skin, as well as complications to fingernails.

The National Psoriasis Foundation states that upwards of 8 million people have the auto-immune skin disorder. Often accompanied by arthritis, psoriasis not only causes scaling of the skin, but complications to fingernails as well.

Affecting everyone from children to adults, psoriasis can lead to anxiety and depression, as individuals with the skin disorder are often afraid of being ridiculed. Usually treated with Humira and Enbrel, psoriasis comes with a shocking price tag and complications that are often difficult to ignore.

Hopeful studies to support the use of CBD for psoriasis

A 2014 study published in the journal Drugs in Context found that Humira had a price tag upwards of $39,000, while Enbrel’s annual cost was around $46,000. Stelara, the most expensive drug, was found to cost over $53,000. As TNF blockers, while medications like Humira help against psoriasis, they can lower the body’s ability to fight infections and cause serious side effects.

Even more interesting, a September 2019 study in London found that, “A number of medications commonly prescribed by rheumatologists may interact with cannabidiol oil” (CBD oil). The most affected medicines appear to be corticosteroids (including hydrocortisone and prednisolone) since CBD, “is a potent inhibitor of CYP3A.” Put plainly, CBD may block the effects of the other medicine.

Often triggered by stress, new studies are showing that psoriasis can be better managed by diet, oral health, and even cannabidiol. The National Psoriasis Foundation shared information on a study from the Journal of Dermatological Science showcasing that, “CBD may offer therapeutic value for psoriasis by slowing the overgrowth of certain skin cells.”

A 2016 study published by the National Institute of Health found similar results, citing that cannabinoids may be a positive addition to treatment for psoriasis. Even better, a 2018 study did a sweeping review of prior research on cannabis’ role within dermatology and found, “cannabinoids have shown some initial promise as a therapy for a variety of skin diseases.” Their only concern was a lack of research in clinical trials, due to the Schedule 1 classification of the drug.

While CBD and cannabis offer pain relief and psoriasis is often accompanied by rheumatoid arthritis, each individual must discuss the addition of any new medicine (including CBD and cannabis) with their care team. With new clinical trials for cannabinoids and psoriasis recruiting even now, promising cures may be on the horizon.

 

Source: 420intel


cannabis-for-the-eye-1200x767.jpg
05/Feb/2020

Could cannabis become a therapeutic option for the eye?

In about 20 to 30 percent of patients with dry eyes, the pain does not decrease to a tolerable level despite tear substitutes and anti-inflammatory ophthalmic drugs, such as Ciclosporin A. The pain is caused by the use of a combination of the two drugs. Here, newly developed cannabis-containing eye drops could become a therapeutic option.

This was announced by Professor Dr. Philipp Steven of the University Hospital Cologne at a press conference of the German Ophthalmological Society in Berlin. The use of the ingredient tetrahydrocannabinol (THC) in the eye is plausible because it not only has an analgesic effect but also has an anti-inflammatory and wound healing promoting effect. The cornea as well as the conjunctiva of the eye have many endocannabinoid receptors.

Adding cannabinoids in eyedrops

Like other cannabinoids, THC is only poorly soluble in water, which was previously an obstacle to its use on the eye. Steven’s research group and a pharmaceutical company from Heidelberg have investigated the galenic problem and developed THC-containing eye drops based on anhydrous semifluorinated alkanes (SFA). These are linear molecules with a perfluorocarbon and a hydrogen carbon content.

Steven explained that the THC-SFA eye drops, for which a patent application had been filed, could be used to apply large amounts of the active ingredient to the eye surface. In experiments with mice, the use of eye drops has led to a significant improvement in dry eyes and the function of the nerve endings.

Source: https://ptaforum.pharmazeutische-zeitung.de/cannabis-fuers-auge/


myofascial_pain-1200x614.jpg
29/Jan/2020

CBD reduced pain in patients with myofascial pain in placebo controlled study

In a placebo-controlled study with 60 patients suffering from pain in the face topical CBD significantly reduced pain and muscle activity of the masseter, a face muscle.

Patients received either topical CBD to the face or a placebo. Pain intensity and muscle activity were measured on days 0 and 14. Pain reduction was 70% and 10% in the placebo group.

Authors concluded that “application of CBD formulation over masseter muscle reduced the activity of masseter muscles and improved the condition of masticatory muscles in patients with myofascial pain.”

Department of Temporomandibular Disorders, Medical University of Silesia in Katowice, Zabrze, Poland.

Nitecka-Buchta A, et al. J Clin Med. 2019;8(11).

Source: http://www.cannabis-med.org/


cbd_treatment_epilepsy-1200x800.jpg
15/Jan/2020

CBD was effective in reducing seizures in children with epilepsy

In a study with 16 patients with epilepsy with an average age of 9 years old, a high-purity CBD preparation reduced the frequency of seizures. The study was conducted at Dana-Dwek Children’s Hospital in Tel Aviv, Israel. This prospective Phase II study was open to pediatric patients with treatment-resistant epilepsy at stable doses of antiepileptic drugs who suffered at least 4 seizures within 4 weeks. After a four-week observation period, patients began a two-week dose titration phase (up to 25mg/kg or 450mg, the lower of the two) followed by a ten-week maintenance treatment.

Of the 16 participants, 11 completed the entire treatment program. The average maintenance dose was 14 mg CBD per kilogram body weight. At the end of the treatment period, there was an average reduction in monthly seizure frequency of 73% compared to baseline. Two patients were completely free of seizures. 73% of the nurses stated that the condition was improved or greatly improved. The most frequently reported treatment-related adverse events were sleep disorders/insomnia (25% of patients), followed by drowsiness, increased seizure frequency, and restlessness (3 patients each (19%)). No side effect was serious or severe and all disappeared by themselves.

Mitelpunkt A, Kramer U, Hausman Kedem M, Zilbershot Fink E, Orbach R, Chernuha V, Fattal-Valevski A, Deutsch L, Heffetz D, Sacks H. The safety, tolerability, and effectiveness vom PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy Behav. 2019;98(Pt A):233-237.

Source: https://www.cannabis-med.org/german/bulletin


cancer-crohn-medical-cannabis-research-1200x960.jpg
19/Dec/2019

Crohn’s disease patients may be able to reduce the risk of cancer with the use of medicinal cannabis

In a study conducted by Atlanta VA Medical Center in Decatur on patients with Crohn’s disease and ulcerative colitis (UC), cannabis use was associated with a lower risk of developing colorectal cancer, anemia and hospitalisation. Among patients with Crohn’s disease, the prevalence of colorectal cancer was 4 times higher among non-users than among cannabis users. The average hospital stay was also shorter (4.2 vs. 5.0 days) with lower hospital costs among cannabis users. In patients with UC, cannabis users experienced a higher incidence of fluid and electrolyte disorders (45% vs. 30%) and hypovolemia (2.7% vs. <11), but a relatively lower incidence of postoperative infections (<11 vs. 3.4%).

Source: https://www.cannabis-med.org/


medical-trials-cannabis-1200x801.jpg
11/Dec/2019

The cannabinoid cannabidivarin (CBDV) is to be tested on patients with autism

A new clinical trial at the Montefiore Medical Center has been put in place to test the effects of cannabidivarin (CBDV) on patients with autism.

Dr Eric Hollander, the lead researcher on this study, has stated that previous research has shown that CBDV could be a potential treatment for children on the spectrum as it has shown positive effects on social functioning and increased cognitive function in animal models.

Autism on the same continuum as Epilepsy

The FDA-approved medicinal cannabis, Epidiolex is mainly prescribed to treat children with epilepsy. It is manufactured by GW Pharmaceuticals who will provide the CBDV for the study. Dr Geoffrey Guy, the founder of GW Pharmaceuticals, states that symptoms of epilepsy are similar to those of autism such as loss of cognitive function, poor socializing skills and poor language skills.

Hollander believes that the electrical activity which causes episodes in epilepsy is similar to those in autism. Using anticonvulsants makes disruptive behaviour becomes less frequent in epileptic patients. Thus, he hypothesises that CBDV should also improve aggression, or the self-injury and temper tantrums in autistic patients.

Opposingly, Dr Alexander Kolevzon, the clinical director of the Seaver Autism Center at Mount Sinai, who is not involved in the study, mentions that it might be too early to tell if it is an effective medication for people on the spectrum.

Source: https://www.countable.us/articles/35397-new-clinical-trial-examine-effects-cannabis-compound-autism


European-Union-cannabis-legal-aspects-1200x708.jpg
04/Dec/2019

Legal Medicinal Cannabis in Europe

As the cannabis market has boomed and new scientific discoveries arise, legislation has become a topic in question which has put a lot of pressure on governments around Europe.

International Drug Policy Consortium Regulations

There are two main kinds of regulation that the International Drug Policy Consortium (IDPC) have established in 2018. The first one comes from the government’s will to improve public health which has resulted into policy. In certain cases, recreational cannabis goes hand in hand with this as well, for example, Canada. The second one comes from the social pressures and the citizen’s initiative to fight for the legalisation which is essentially the case in the UK in which they offer a legal license to patients who comply with strict requirements.

The difficulty in legalising medicinal cannabis

Back in 1961, cannabis was under the Single Convention on Narcotic Drugs meaning it was internationally prohibited, essentially putting an end to medical and scientific research. From this ban, for countries to be able to adopt to the new regulations, there must be irrefutable evidence showcasing the therapeutic uses of the substance. Without the backing of a strong scientific foundation, legalising medicinal cannabis can become challenging.

A few European countries are close to regulating medicinal cannabis

• The United Kingdom

In the UK, the Department of Health was forced to grant emergency licences to two severe cases of epilepsy in children which consequently began a process to allow access to the medicine. However, this is only allowed in certain conditions such as refractory epilepsy, spasticity, multiple sclerosis and chemotherapy induced nausea and vomiting. It is also necessary for the patients to have undergone all kinds of conventional treatments which have failed. After presenting all the necessary documents, only the Department of Health can determine if the patient can gain access.

• Germany

Medicinal cannabis was legalised in Germany in 2017 and is one of the first countries to regulate medicinal cannabis in public and private health sectors. To begin treatment, patients must go through a health insurance company, which will then be reimbursed by the government. Cannabis cultivation is also allowed if companies have enough experience.

• Italy

In 2015, the Italian Minister of Health released a legislation wherein physicians are able to prescribe patients with medicinal cannabis only if the condition can be backed by scientific literature. Similar to the UK, it is only available if previous treatment has failed.

• Denmark

In 2018, the Danish Parliament released a 4-year programme allowing doctors to prescribe medicinal cannabis products only if standard treatments have failed.

• Netherlands

The Netherlands is the only country that does not have the stigma that other countries may have, and doctors’ reputations aren’t tarnished if they prescribe medicinal cannabis. Cannabis in the Netherlands is under a lower classification drug compared to other countries and can also be prescribed by doctors if previous standard treatments have failed.

Is medicinal cannabis a necessity?

The World Health Organisation (WHO) as well as the Expert Committee on Drug Dependence (ECDD) has recommended for cannabis to be removed from the highest classification of drugs and that its therapeutic importance should be recognised. The European Parliament has also made it known that cannabis is a medicinal necessity. On that, as many important entities have had similar statements, medicinal cannabis should be seen as a necessity by everyone.

Source: https://www.kalapa-clinic.com/en/use-medical-cannabis-legal-framework/


dementia-1200x800.jpg
27/Nov/2019

The University of Notre Dame’s Institute for Health Research partners with MGC Pharmaceuticals to conduct the first ever clinical trial using cannabis as a treatment for dementia.

The actual trial is due to commence in early 2020 and will take place over 14 months and they are aiming to enrol 50 participants aged 65 and older with mild dementia or Alzheimer. The University of Notre Dame in Western Australia’s (UNDA)’s Human Research Ethics Committee (HREC) approved all ethical concerns, ensuring the safety and well-being of the participants as well as bringing together medical experts, elder care practitioners and industry stakeholders. By partnering with MGC Pharmaceuticals, who have operations in Israel, Slovenia, Czech Rep, the UK and Australia, UNDA will be provided with a specially formulated medical cannabis product called CogniCann. According to MGC Pharmaceuticals, it is a specially blended CBD-THC oral-spray medication formulated to specifically treat dementia symptoms.

Is dementia treatment a national priority?

As 350,000 Australians are already living with some form of dementia, the number is to double in 40 years with an additional 1.5 million people currently involved in the care of someone with dementia. The Institute for Health Research’s director, Jim Codde, finds that dementia research should be “a national priority” to end the suffering of a disease that has no cure. In the end, finding a cure can improve that life of the patient, and more than anything, for families and caregivers too.


heart-attack-cannabinoids-1200x800.jpg
20/Nov/2019

Literature reports the potential effects that cannabis can have in cardiovascular complications.

Acute myocardial infarction (AMI) is more commonly known as a heart attack, which can lead to heart failure. In a multivariable analysis, it revealed that marijuana use can lead to an increased risk in AMI development, however, THC and CBD may have opposing effects. THC decreases in contractile force and coronary flow, while also inducing an increased frequency. On the other hand, CBD can increase contractile force and coronary flow, but it does not change the heart rate.

Investigations about mortality post AMI and medical cannabis

Moreover, a new study in 2018 was carried out on the relationship between patients who suffered a heart attack from 1994 – 2013 and the use of cannabis. The results showed a reduced mortality post AMI. An explanation to this can be a hint on the possible cardiac infarct preventative effects in cannabis. Although cannabis has this positive effect, consumers can still have an increased risk of mechanical ventilation after a heart attack.

Therefore, the results show clear evidence that cannabis is not associated with an increased risk, as opposed to the assumptions that it can cause unfavourable effects after a heart attack.

Source https://www.kalapa-clinic.com/en/cannabis-reduce-mortality-heart-attack/


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos-3

OFFICES

CanPharma GmbH
Wiesbadener Str. 29,
16515 Oranienburg, Germany

 

REPRESENTATIVE OFFICES

Berlin
Rosenthaler Str. 34
10178 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain